NCEL

NewcelX Ltd

2.72

Nov 06 • 3:59 PM ET -0.17 (-5.73%)

2.76

Aftermarket • 7:30 PM ET +0.04 (1.31%)

Healthcare Biotechnology Switzerland Nano NASD

Peers: LGVN SANA ENLV NRSN PLUR CLNN BCDA BRTX CELZ MESO

Scroll to Statements

Index	-
Market Cap	14.67M
Enterprise Value	14.35M
Income	-
Sales	-
Book/sh	1.12
Cash/sh	0.13
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	12
IPO	Jan 29, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	2.43
P/C	20.66
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	0.32
Current Ratio	0.32
Debt/Eq	0.06
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	81.39% 60.94%
Sales past 3/5Y	- -
EPS Y/Y TTM	77.07%
Sales Y/Y TTM	-
EPS Q/Q	86.03%
Sales Q/Q	-
Earnings	Sep 02
EPS/Sales Surpr.	0.00% -

Insider Own	52.90%
Insider Trans	0.00%
Inst Own	0.23%
Inst Trans	-86.36%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	1.56%
SMA50	-7.71%
SMA200	-12.31%
Trades

Shs Outstand	5.38M
Shs Float	2.54M
Short Float	0.39%
Short Ratio	0.73
Short Interest	0.01M
52W High	5.12 -46.79%
52W Low	1.83 48.88%
Volatility	13.61% 13.30%
ATR (14)	0.31
RSI (14)	48.76
Beta	1.01
Rel Volume	0.84
Avg Volume	13.43K
Volume	11,244

Perf Week	6.84%
Perf Month	-12.40%
Perf Quarter	-16.17%
Perf Half Y	-18.92%
Perf YTD	43.39%
Perf Year	-34.35%
Perf 3Y	-98.99%
Perf 5Y	-99.68%
Perf 10Y	-
Recom	1.00
Target Price	23.00
Prev Close	2.89
Price	2.72
Change %	-5.73%

Nov-04-26 08:00AM	NewcelX Enters into Binding Term Sheet to Divest Legacy Mazindol Portfolio (CVR), Providing for Upfront Cash, Equity Ownership and Up to $55 Million in Potential Milestone Payments (GlobeNewswire)
Sep-28-26 08:00AM	NewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission to Develop a Cure for Type 1 Diabetes (GlobeNewswire)
Jul-31-26 09:00AM	NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing (GlobeNewswire)
Jul-15-26 09:00AM	NewcelX Granted Patent in Brazil for NCEL-101 in Type 1 Diabetes, Expanding Global IP Portfolio (GlobeNewswire)
Jul-08-26 09:15AM	NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board (GlobeNewswire) +5.49%
09:00AM	Loading…
09:00AM	The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy (PR Newswire)
Jul-01-26 09:30AM	NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes (GlobeNewswire) +5.19%
May-27-26 07:55AM	NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes (GlobeNewswire) +9.52%
Apr-30-26 08:15AM	NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026 (GlobeNewswire) +28.95%
Apr-20-26 07:37AM	NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference (GlobeNewswire) +6.39%
Apr-01-26 07:21AM	NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing (GlobeNewswire) +10.85%
Mar-10-26 06:44AM	NewcelX and Eledon partner for NCEL-101 programme (Pharmaceutical Business Review)
Mar-09-26 07:00AM	NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes (PR Newswire)
Feb-12-26 07:00AM	NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy (PR Newswire)
Jan-29-26 07:00AM	NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences (PR Newswire)
07:00AM	Loading…
Jan-12-26 07:00AM	NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression (PR Newswire) +13.70%
Jan-05-26 07:00AM	NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board (PR Newswire) +6.70%
Dec-11-25 07:00AM	NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China (PR Newswire) -21.83%
Nov-17-25 07:00AM	NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute (PR Newswire)
Nov-06-25 07:00AM	NewcelX Announces Scientific Leadership with the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory Board (PR Newswire) -11.70%
Nov-04-25 07:00AM	NewcelX CEO Issues Letter to Shareholders (PR Newswire) +10.02%
Nov-03-25 08:25AM	NewcelX Provides Business and Strategic Roadmap Update Following Closing of Merger with NLS Pharmaceutics Ltd. (PR Newswire) -29.49%
Oct-30-25 04:15PM	NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger (PR Newswire)
07:00AM	NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs (PR Newswire)
Oct-29-25 07:00AM	NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger (PR Newswire) -29.52%
06:00AM	NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem (PR Newswire)
03:53AM	NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares (PR Newswire)
Oct-27-25 07:00AM	NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies (PR Newswire)
Oct-23-25 06:01AM	NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025 (PR Newswire) -16.98%
Sep-30-25 07:00AM	NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting (PR Newswire) -25.31%
06:00AM	Loading…
Sep-10-25 06:00AM	Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger (PR Newswire) +6.70%
Sep-04-25 07:38AM	NLS Pharmaceutics and Kadimastem announce a Hong Kong Patent Covering Cell-Selection and Enrichment Technology for IsletRx for Diabetes Patients (PR Newswire)
Jul-17-25 07:00AM	NLS Pharmaceutics Highlights Continued Progress in iTOL-102 Diabetes Program as BIRD Foundation Approves Additional Milestone Payment to Kadimastem and iTolerance for Continued Co-Development of Type 1 Diabetes Cell Therapy (PR Newswire)
Jun-30-25 07:00AM	NLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity Financing (PR Newswire)
Jun-16-25 07:00AM	NLS Pharmaceutics CEO Issues Letter to Shareholders (PR Newswire)
May-21-25 07:30AM	NLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting (PR Newswire)
Apr-15-25 09:00AM	NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models (PR Newswire)
Mar-31-25 09:10AM	NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement (ACCESSWIRE) +18.46%
Mar-10-25 07:00AM	NLS Pharmaceutics CEO Issues Letter to Shareholders (PR Newswire)
Feb-27-25 07:00AM	NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform (PR Newswire)
Feb-25-25 09:05AM	Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment (PR Newswire)
Feb-10-25 07:30AM	NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies (PR Newswire) +37.43%
Jan-31-25 07:30AM	Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics (PR Newswire) +25.76%
Jan-30-25 07:30AM	NLS Pharmaceutics Announces the Submission of Three Research Abstracts to the 2025 ASCP Annual Meeting (PR Newswire)
Jan-28-25 07:30AM	NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence (PR Newswire)
Jan-16-25 09:32AM	Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS (PR Newswire)
Jan-09-25 08:28AM	NLS Pharmaceutics and Kadimastem Advance Merger Plans with $500,000 Fundraising (TipRanks)
Jan-08-25 07:42AM	NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its Extraordinary General Meeting at a Share Price of $3.10, Representing 48% Above the Market Share Price as of Jan 6, 2025 (PR Newswire) +16.99%
Dec-30-24 07:30AM	NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger (PR Newswire) +49.45%
Dec-19-24 07:30AM	NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment (ACCESSWIRE) +19.00%
Dec-12-24 07:45AM	NLS Pharmaceutics expects to close Kadimastem merger by end of January (TipRanks)
Dec-11-24 07:30AM	NLS Pharmaceutics CEO Issues Letter to Shareholders (ACCESSWIRE)
Dec-04-24 01:15PM	NLS Pharmaceutics Ltd. Announces Pricing of Private Placement of up to $1 Million at a 15% Premium to the Market (PR Newswire)
Dec-03-24 07:40AM	NLS Pharmaceutics Announces Promising Preclinical Data for First-in-Class Non-Sulfonamide, Dual Orexin Receptor Agonists for the Potential Treatment of Narcolepsy and Neurological Disorders (ACCESSWIRE) -11.22%
Nov-18-24 07:30AM	NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders (ACCESSWIRE)
Nov-05-24 07:31AM	NLS Pharmaceutics, Kadimastem enter definitive merger agreement (TipRanks) -7.97%
Nov-04-24 07:00AM	NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement (ACCESSWIRE) +21.94%
Oct-28-24 07:00AM	NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements (ACCESSWIRE)
Oct-21-24 07:00AM	NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence (ACCESSWIRE) -10.19%
Oct-19-24 04:57PM	NLS Pharmaceutics Sees Reduced Losses Amid Financial Challenges (TipRanks)
Oct-15-24 07:00AM	NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing Rules (ACCESSWIRE)
Sep-25-24 08:00AM	NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split (ACCESSWIRE)
Jul-29-24 11:58AM	Tivic Health Systems (TIVC) Stock Pops Another 39% (InvestorPlace) +23.05%
07:00AM	NLS Pharmaceutics and Kadimastem Announce Binding Term Sheet to Merge (ACCESSWIRE)
Jun-28-24 09:00AM	NLS Pharmaceutics Announces Registered Direct Offering (ACCESSWIRE) -9.62%
Jun-27-24 08:00AM	NLS Pharmaceutics Announces Promising Preclinical Results for Parkinson's Disease Treatments (ACCESSWIRE) +31.43%
Jun-25-24 08:30AM	Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Requirements (ACCESSWIRE) -5.61%
Jun-20-24 09:47AM	PLTR Stock: Palantir Bags New Partnership With ARPA-H for AI/ML (InvestorPlace) -30.80%
08:38AM	Why Is NLS Pharmaceutics (NLSP) Stock Down 23% Today? (InvestorPlace)
07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
Jun-18-24 07:54AM	Why Is NLS Pharmaceutics (NLSP) Stock Up 163% Today? (InvestorPlace) +82.13%
07:37AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
Jun-11-24 08:30AM	NLS Pharmaceutics Announces Publication of New Patent Application for Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists (DOXA) (ACCESSWIRE) +6.33%
May-28-24 08:00AM	NLS Pharmaceutics Reports Positive Results from Study KO-874 on Mazindol's Neuroprotective Effects in Narcoleptic-like Rat Model (ACCESSWIRE)
May-24-24 05:00PM	NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from Nasdaq (ACCESSWIRE)
Apr-19-24 05:00PM	NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing (ACCESSWIRE)
Mar-22-24 04:30PM	NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering (ACCESSWIRE) +5.94% -8.06%
Mar-20-24 01:40PM	NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering (ACCESSWIRE) -41.72%
07:30AM	NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform (ACCESSWIRE)
Mar-14-24 08:00AM	NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event (ACCESSWIRE)
Mar-11-24 07:00AM	Nasdaq Accepts NLS Pharmaceutics' Plan to Regain Listing Compliance (ACCESSWIRE) +8.97%
Feb-23-24 07:30AM	NLS Pharmaceutics Submits Plan to Regain Listing Compliance With Nasdaq (ACCESSWIRE)
Jan-12-24 04:30PM	Notice of Deficiency with Nasdaq Continued Listing Requirements (ACCESSWIRE) -7.88%
Dec-29-23 04:30PM	NLS Pharmaceutics CEO Issues Letter to Shareholders (ACCESSWIRE) +16.60%
Dec-04-23 09:06AM	Why Is NLS Pharmaceutics (NLSP) Stock Down 24% Today? (InvestorPlace) -8.20%
07:21AM	10 Best Debt Free Penny Stocks To Buy Now (Insider Monkey)
Dec-01-23 07:30AM	NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc. (ACCESSWIRE) +45.27%
Nov-28-23 07:30AM	NLS Pharmaceutics Announces Election of Additional Board Members (ACCESSWIRE)
Nov-27-23 08:30AM	NLS Pharmaceutics to Participate in the Oppenheimer Sleep Disorders Summit: Deep Dive into Narcolepsy and Idiopathic Hypersomnia (ACCESSWIRE)
Nov-16-23 08:00AM	NLS Pharmaceutics Announces Selection of Strategic Partner and Securing a Bridge Loan (ACCESSWIRE) -34.44%
Oct-25-23 04:30PM	NLS Pharmaceutics Announces Receipt of Nasdaq Minimum Bid Price Notification (ACCESSWIRE) -7.14%
Oct-19-23 05:00PM	NLS Pharmaceuticals to Reschedule Company Update on Strategic Discussions (ACCESSWIRE) -15.03%
Oct-12-23 09:40AM	NLS Pharmaceutics Announces Company Update on Strategic Partnerships (ACCESSWIRE) -12.63%
Aug-28-23 07:30AM	NLS Pharmaceutics CEO Issues Letter to Shareholders (ACCESSWIRE) +9.63%
Jul-03-23 07:00AM	NLS Pharmaceutics to Proceed with Phase 3 Clinical Program (AMAZE) for Mazindol ER for the Treatment of Narcolepsy Following FDA Review and IRB Approval of the Full Study Protocol (ACCESSWIRE) +9.09%
Jun-30-23 04:05PM	NLS Pharmaceutics Releases the Results from its Annual General Meeting (ACCESSWIRE) +19.57%
08:00AM	NLS Pharmaceutics Company Update and Webcast Today Postponed (ACCESSWIRE)
Jun-19-23 07:30AM	CORRECTION FROM SOURCE: NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest (ACCESSWIRE)
07:10AM	NLS Pharmaceutics Announces Company Update Webcast (ACCESSWIRE)
Jun-15-23 08:30AM	NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest (ACCESSWIRE) +6.01%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Samuel Olivier	Director	Apr 27 '26	Buy	2.75	81,818	225,000	81,818	Apr 29 04:05 PM
Revel Michel	CSO and Director	Apr 27 '26	Buy	2.75	54,545	149,999	957,530	Apr 29 04:05 PM

NewCelX Ltd. is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company is headquarter in Kloten, Switzerland.

CEO & Executive ChairmanMr. Ronen Twito CPA

Ph.D.Prof. Michel Revel M.D.

Chief Financial OfficerMr. Omri Hagai

Chief Business Officer & Executive DirectorMr. Alexander C. Zwyer M.B.A.

Ph.D.Dr. Eric Konofal M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NCEL

NewcelX Ltd

Upgrade your Finviz experience